Working With An Investment Banker

I frequently serve as a guest speaker at many life sciences networking events across the United States and internationally targeted at entrepreneurs and business owners in start-up companies within the Life Sciences segment. This article will cover the value of an investment banker, what activities they perform, and why you need to consider building a relationship with and hiring an investment banker for your growth and exit plans.

The Value of the Investment Banker to Your Life Science Business

Investment bankers add value for 100% of business owners including sellers, licensors, and those seeking capital. In a 2016 study involving CEOs, one-hundred percent of owners who sold their business with the help of an investment banker said yes, according to a recent study from Fairfield University professor Dr. Michael McDonald, titled “The Value of Middle Market Investment Bankers”. Sixty-nine percent said that the value added by bankers was “significant”.

M&A, partnering, and capital financing processes with sophisticated investors are complex transactions, and sellers have a few inherent disadvantages that can make the process more difficult, including:

• Lack of experience: The company founder or CEO is typically an expert in science, technology, or operations but not in running an M&A process.
• Managing the process: Running a sophisticated transaction process is a full-time job that requires deep experience with legal and financial complexity.
• Emotional attachment: An owner is naturally protective and emotionally invested in the business, which can negatively impact negotiations.
• Detachment from the process: An investment banker is financially and professionally incentivized to remain detached, focused solely on achieving the best possible outcome for the client.

In the highly specialized and constantly evolving Life Sciences sector, these disadvantages are amplified by the unique nature of dealmaking in 2025. Life Sciences transactions are distinguished by multiple layers of intellectual property (IP) ownership, complex regulatory and reimbursement hurdles, and the core challenge of determining and agreeing upon a valuation for an intangible, pre-commercial pipeline asset.

Life Sciences M&A Trends & Market Dynamics in 2025

After a period of market caution, M&A activity in the life sciences sector is experiencing a strong rebound in 2025. This surge is primarily fueled by two macro drivers: Big Pharma’s pressing need for innovation and a more favorable regulatory environment.

Key Trends Driving Deal Flow

1. Filling Pipeline Gaps and Patent Cliffs: A major catalyst is the looming patent cliff, with approximately $300 billion in industry revenues potentially affected by patent expirations within the next few years. Large pharmaceutical companies are deploying their significant war chests—collectively reported to hold over a trillion dollars in deployable capital—to acquire late-stage and pre-commercial assets to offset this revenue erosion.
   
   
2. Hot Therapeutic Areas: The competition for assets in specific therapeutic niches is intense, often referred to as a “land grab”.
   • Metabolic Disease/MASH: Acquisitions in the Metabolic Dysfunction-associated Steatohepatitis (MASH) and obesity space are a dominant theme, with major pharmaceutical companies committing billions in upfront consideration to secure FGF21 analogs and other key assets.
   • String-of-Pearls Strategy: Large-cap biopharma continues to pursue early- to mid-stage innovation using a “string-of-pearls” approach, with oncology, immunology, and rare disease assets leading the activity in the $1 billion to $10 billion deal range.
     
     
3. Alternative Deal Structures to Bridge Valuation Gaps: Due to the significant binary value outcomes inherent in drug development, achieving consensus on valuation remains challenging. Investment bankers are increasingly structuring deals with Contingent Consideration to bridge these gaps, including:
   • Earn-outs: Tying additional payments to the achievement of specific, measurable development or commercial milestones.
   • Contingent Value Rights (CVRs): Used in public company transactions, these rights grant shareholders an additional payout if certain future events (like regulatory approval) occur.
     
     
4. Rise of Private Equity and Dual-Track Processes: Private Equity (PE) firms are becoming more active in the life sciences, bringing long-term capital to a sector where companies are staying private longer due to volatility in IPO markets. Furthermore, as capital markets strengthen, companies are increasingly adopting dual-track processes—simultaneously preparing for both an IPO and an M&A exit—to maximize optionality, boost valuations, and force potential buyers to act quickly.

The Investment Banker as Your Critical Navigator Heading Into 2026

The complexity and dynamism of the 2025 Life Sciences M&A market make the role of a specialized investment banker more critical than ever. An experienced advisor is not merely an administrator of the process, but a strategic guide who must operate at the intersection of science, finance, and regulatory policy.

How Investment Bankers Add Depth and Value in the Current Market

• Structuring Complex Transactions: The ability to move beyond a simple cash-for-stock deal is paramount. Investment bankers specialize in designing and negotiating the creative, risk-shared deal structures (e.g., CVRs, earn-outs) that are essential for bridging the valuation gap between sellers (who see future upside) and buyers (who need to mitigate development risk).
  
  
• Specialized Due Diligence Management: Unlike traditional M&A, most of the value in a Life Sciences company is linked to intangible assets. The IB coordinates comprehensive, specialized due diligence in areas critical for deal success and valuation:
  • Intellectual Property (IP) Review: The quality and defensibility of patents are central to the asset’s value.
  • Regulatory & Compliance: Assessing the risk and predictability of FDA approval timelines and the impact of evolving policies (such as the Inflation Reduction Act or new tariff policies) is a key factor in pricing assets.
  • ESG Integration: With growing importance placed on Environmental, Social, and Governance (ESG) factors, bankers are integrating ESG due diligence to identify risks and potential value opportunities.
    
    
• Strategic Alternatives for Middle Market Companies: For middle-market biotechs facing capital market caution, the IB is instrumental in evaluating strategic options beyond a full sale. This includes exploring alternatives like asset monetization (selling off certain pipeline products while retaining the core platform) or orchestrating combination mergers to achieve scale and rationalize resources—a “combine to survive” strategy expected to increase in 2025.
  
  
• Leveraging Technology for Efficiency: Leading investment banks are integrating advanced data analytics and Generative AI tools into the deal lifecycle to enhance efficiency. AI is used to streamline deal sourcing, identify target companies, and conduct faster, more accurate due diligence by reviewing vast amounts of financial and contractual data.

There will be challenges along the way. Buyers or investors will ask many difficult questions during the due diligence process, potentially disagreeing with your valuation and views of the market for your exciting technology. They will challenge your assumptions and question the proposed product differentiation that you believe you will achieve.

Choosing an experienced advisor who will anticipate these challenges and proactively address issues will help put you in a better position as you begin meeting and negotiating with buyers, partners, and investors. Good advisors are those that not only have the right experience but also have the demonstrated abilities to adapt to changing market conditions and apply techniques for the unique nuances of your company.

Disclosure

David H. Crean, Ph.D., is a Managing Partner for Cardiff Advisory LLC, an M&A investment banking strategic advisory firm focused on the Life Sciences and Healthcare sectors. This article is provided for informational purposes only and does not constitute an offer, invitation, or recommendation to buy, sell, subscribe for or issue any securities.

The principals of Cardiff Advisory LLC are registered representatives of BA Securities, LLC Member FINRA SIPC, located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 400 W. Conshohocken, PA 19428. Cardiff Advisory LLC and BA Securities, LLC are unaffiliated entities. All investment banking services and securities are offered through BA Securities, LLC, Member FINRA SIPC.